Omeprazole - ClinicalTrials.gov

Effects of GSK3640254 on the Single-Dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin) in Healthy Subjects

On Day 1, participants will be given a single dose of probe substrate drug. On Days 11 to 20, participants will then receive GSK3640254 200 mg per day for the first time daily, followed by co-administration of probe substrate drugs with GSK3640254 on Day 21.

Source link: https://clinicaltrials.gov/ct2/show/NCT04425902

A Phase 1, 2-Part, Multicenter, Open-Label, 3-Arm Study to Determine the Effect of Enasidenib (CC-90007) on the Pharmacokinetics of Single Oral Doses of Caffeine, Dextromethorphan, Fexofenadine, Flurbiprofen, Midazolam, Omeprazole, Pioglitazone, and Rosuvastatin in Patients With Acute Myeloid Leukemia

Single doses of caffeine, dextromethorphan, flurbiprofen, midazolam, and omeprazole were included in Arm 1's investigations. The Arm 3 probe is pioglitazone, according to pioglitazone. The probes will be launched on Day -1, followed by the first dose of enasidenib on Day 1 in Part 1. On Day 28, the probes will be administered for the second time. The subject will begin a second round of daily enasidenib doses on the next day, while Part 2 of the trial begins the next day.

Source link: https://clinicaltrials.gov/ct2/show/NCT03720366

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions